Page 1 | Search Results | Blood | American Society of Hematology

1-5 of 5

Sort by

Sort Order Select

Journal Articles

Phase I/II Study of Oral Fodosine TM , a PNP Inhibitor in Refractory Cutaneous T-Cell Lymphoma Patients.

Madeleine Duvic, MD, Debra Breneman, MD, Maureen Cooper, MD, Gustavo Fonseca, MD, J. Claude Bennett, MD, J. Michael Kilpatrick, PhD, Shanta Bantia, PhD

Blood (2005) 106 (11): 2683.

https://doi.org/10.1182/blood.V106.11.2683.2683

Published: 2005

Journal Articles

Forodesine (Fodosine TM ), a PNP Inhibitor Active in Relapsed or Refractory T-Cell Leukemia Patients (Phase II Study).

Richard R. Furman, MD, Genadi Iosava, MD, Luis Isola, MD, Farhad Ravandi, MD, Mamia Zodelava, MD, J. Claude Bennett, MD, J. Michael Kilpatrick, PhD, Shanta Bantia, PhD, Fodosine Development Group

Blood (2005) 106 (11): 881.

https://doi.org/10.1182/blood.V106.11.881.881

Published: 2005

Journal Articles

Antileukemic Activity and Pharmacodynamics of Intravenous Forodesine (BCX-1777), a Novel Purine Nucleoside Phosphorylase (PNP) Inhibitor, in Phase I/II Trials in Patients with Advanced T-Cell Malignancies.

Luis Isola, MD, Richard R. Furman, MD, Varsha Gandhi, PhD, Deborah A. Thomas, MD, J. Claude Bennett, MD, Shanta Bantia, PhD, J. Michael Kilpatrick, PhD

Blood (2004) 104 (11): 4501.

https://doi.org/10.1182/blood.V104.11.4501.4501

Published: 2004

Journal Articles

Intravenous Forodesine (BCX-1777), a Novel Purine Nucleoside Phosphorylase (PNP) Inhibitor, Demonstrates Clinical Activity in Patients with Refractory Cutaneous T-Cell Lymphoma.

Madeleine Duvic, MD, Francine M. Foss, MD, Elise A. Olsen, MD, Andres Forero-Torres, MD, J. Claude Bennett, MD, Shanta Bantia, PhD, J. Michael Kilpatrick, PhD

Blood (2004) 104 (11): 2491.

https://doi.org/10.1182/blood.V104.11.2491.2491

Published: 2004

Journal Articles

Intravenous Forodesine (BCX-1777), a Novel Purine Nucleoside Phosphorylase (PNP) Inhibitor, Demonstrates Clinical Activity in Phase I/II Studies in Patients with B-Cell Acute Lymphoblastic Leukemia.

Richard R. Furman, MD, Varsha V. Gandhi, PhD, J. Claude Bennett, MD, Shanta Bantia, PhD, J. Michael Kilpatrick, PhD

Blood (2004) 104 (11): 2743.

https://doi.org/10.1182/blood.V104.11.2743.2743

Published: 2004

NARROW

Phase I/II Study of Oral Fodosine TM , a PNP Inhibitor in Refractory Cutaneous T-Cell Lymphoma Patients.

Forodesine (Fodosine TM ), a PNP Inhibitor Active in Relapsed or Refractory T-Cell Leukemia Patients (Phase II Study).

Antileukemic Activity and Pharmacodynamics of Intravenous Forodesine (BCX-1777), a Novel Purine Nucleoside Phosphorylase (PNP) Inhibitor, in Phase I/II Trials in Patients with Advanced T-Cell Malignancies.

Intravenous Forodesine (BCX-1777), a Novel Purine Nucleoside Phosphorylase (PNP) Inhibitor, Demonstrates Clinical Activity in Patients with Refractory Cutaneous T-Cell Lymphoma.

Intravenous Forodesine (BCX-1777), a Novel Purine Nucleoside Phosphorylase (PNP) Inhibitor, Demonstrates Clinical Activity in Phase I/II Studies in Patients with B-Cell Acute Lymphoblastic Leukemia.

Email alerts

ASH Publications

American Society of Hematology

Phase I/II Study of Oral Fodosine TM , a PNP Inhibitor in Refractory Cutaneous T-Cell Lymphoma Patients.

Forodesine (Fodosine TM ), a PNP Inhibitor Active in Relapsed or Refractory T-Cell Leukemia Patients (Phase II Study).

Antileukemic Activity and Pharmacodynamics of Intravenous Forodesine (BCX-1777), a Novel Purine Nucleoside Phosphorylase (PNP) Inhibitor, in Phase I/II Trials in Patients with Advanced T-Cell Malignancies.

Intravenous Forodesine (BCX-1777), a Novel Purine Nucleoside Phosphorylase (PNP) Inhibitor, Demonstrates Clinical Activity in Patients with Refractory Cutaneous T-Cell Lymphoma.

Intravenous Forodesine (BCX-1777), a Novel Purine Nucleoside Phosphorylase (PNP) Inhibitor, Demonstrates Clinical Activity in Phase I/II Studies in Patients with B-Cell Acute Lymphoblastic Leukemia.

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only